Biosimilars and the BSR Biologics Registers
A biosimilar medicine is a biological medicine manufactured to be similar to an existing licensed “reference” biological medicine, with no meaningful differences from the reference medicine in terms of quality, safety or efficacy. The first biosimilars for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis were introduced to the UK in February 2015.
“The BSR strongly recommends that all patients starting or switching to biosimilars should be registered with the BSRBR to allow the capture of the same robust systematic data on adverse effects that have been collected for the reference medicines. The data will ultimately allow clinicians and patients to make informed choices about treatment options.”
BSR Position Statement (February 2015)
Summary of page content:
BSR Position Statement
Other organisations Position Statements
Biosimilars in Perspective – conference session slides
Frequently Asked Questions
BSR have set out its policy position on biosimilars:
The BSR Biologics Register for Rheumatoid Arthritis are now recruiting patients who are prescribed the biosimilar drugs Benepali, Inflectra and Remsima.
We are recruiting participants with RA who are within 6 months of
newly starting or switching to treatment with a biosimilar product. A patient will also be eligible for re-registration if they are already on the register and switch to a biosimilar.
Find out more about the biologics recruitment pathway.
Please use forms below to collect the patient information or contact the project team for further information -
We have no current plans for the BSR register for Ankylosing Spondylitis to register new patients on biosimilars drugs, although patients already registered with us and switching to biosimilar drugs will be followed.
The BSR recommends that for patients with AS, Psoriatic Arthritis or other non-RA diseases being prescribed a biosimilar that consultants collect the information in our RA forms and store it locally.
Please use the following PDF forms:
Regulatory Guidance Bodies
At the 2014 Rheumatology Conference BSR organised a session “Biosimilars in Perspective”. Please see these slides for further information on Biosimilars:
BSR would like to support all the rheumatology community and so we aim to present a list of answers to FAQ here. Please send any questions to: